DiamiR and AlzLabs Team Up on Blood-Based Alzheimer's Biomarkers
DiamiR Biosciences and AlzLabs Precision Diagnostics announce a collaboration to develop protein and microRNA blood biomarkers for Alzheimer's disease.
DiamiR Biosciences Corp. and AlzLabs Precision Diagnostics announced Monday a joint collaboration to generate blood-based biomarker data targeting Alzheimer's disease, with a focus on protein and microRNA signatures detectable through routine blood tests. The partnership was disclosed by Aptorum Group Limited (NASDAQ: APM), the clinical-stage biopharmaceutical company that counts DiamiR among its portfolio companies.
The collaboration centers on two complementary diagnostic approaches: protein biomarkers and microRNA biomarkers — both drawn from blood samples rather than more invasive methods such as cerebrospinal fluid testing or costly PET imaging. Combining these two data streams could potentially improve the sensitivity and specificity of early Alzheimer's detection, a major unmet need in neurology.
Read more SK Hynix Tops Samsung; Apple Warns of Imminent Price Hikes →
DiamiR has positioned itself as a developer of innovative blood-based diagnostic tests for brain health and other diseases, making the AlzLabs partnership a strategic extension of its core mission. AlzLabs Precision Diagnostics brings complementary expertise in Alzheimer's-specific diagnostic frameworks, with the two organizations based across New Haven, CT, and Princeton, NJ, respectively.
Early and accurate Alzheimer's diagnosis remains one of the most pressing challenges in medicine, as current clinical tools often identify the disease only after significant neurological damage has occurred. Blood-based biomarker platforms, if validated, could dramatically expand access to screening by lowering cost and procedural burden — representing a significant commercial and clinical opportunity for both companies and their backers.
Continue reading at GlobalNewswire.
